Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 September 2019 | Story Ruan Bruwer
Louzanne  and her guide, Estean Badenhorst.
Louzanne Coetzee ran a new national record time in the 1 500 m in Paris. Pictured with her is her guide, Estean Badenhorst.

The blind UFS athlete Louzanne Coetzee has broken yet another national record.

The South African 1 500 m record in the T11 classification (totally blind) will have the same name next to it, but a new time – as the previous record also belonged to Coetzee.

She clocked a personal best time of 4:51:65 at the Paris Para Athletics Grand Prix meeting over the weekend. The previous record was set at the World Para Championships in London in July 2017. Coetzee is also the world record holder in the 5 000 m and the African record holder in the 800 m.

Her time in Paris is good enough to take her to a second Paralympic Games. The qualification standards for the games in Tokyo is 06:20.00.

Estean Badenhorst – as her guide – accompanied her. “I have run with him before but couldn’t make use of his services last year due to his study commitments. It is a great privilege to run with him. Estean is a fantastic strategic guide. I hope we can join forces again in the future,” Coetzee said. 

Emphasis now on 1 500 m 

The 800 m and 5 000 m are not on the Paralympic programme; this shifted her focus to the 1 500 m, in which she will participate at the World Para Athletics Championships in Dubai in early November.

“This is now my main focus in the run-up to the Paralympics next year,” says Louzanne. 

She has already qualified for the Paralympics in the marathon, but this will play second fiddle to the track, said the 26-year-old, who is doing her master’s in Social Cohesion and Reconciliation Studies this year.

According to Rufus Botha, a respected athletic coach who previously coached Coetzee, her time in Paris was excellent. “This predicts a great World Champs where Louzanne seems ready for her first medal at a World Championship,” he said.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept